<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Eagle Pharmaceuticals, Inc. 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=24346></link><description><![CDATA[Eagle Pharmaceuticals, Inc. 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Thu, 14 May 2026 09:11:47 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><language>ko-KR</language><item><title><![CDATA[FDA Grants Seven Years’ Market Exclusivity to Eagle Pharmaceuticals’ Ryanodex for the Treatment of Malignant Hyperthermia]]></title><link>https://www.newswire.co.kr/newsRead.php?no=783658</link><description><![CDATA[WOODCLIFF LAKE, N.J.--(Business Wire/Korea Newswire)--Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (Nasdaq:EGRX) today confirmed that the U.S. Food and Drug Administration (FDA) has granted seven years of market exclusivity in the U.S. to Ryanodex® (dantrolene sodium) for Injectable Suspension for the treatment of malignant hyperthermia (MH). Ryanodex was designated an orphan drug in Augu...]]></description><pubDate>Tue, 24 Feb 2015 11:55:00 +0900</pubDate></item><item><title><![CDATA[FDA, 이글 파마슈티컬스의 악성고열증 치료제 ‘라이아노덱스’에 7년간 시장독점 허용]]></title><link>https://www.newswire.co.kr/newsRead.php?no=783659</link><description><![CDATA[우드클리프 레이크, 뉴저지--(Business Wire/뉴스와이어)--이글 파마슈티컬스(Eagle Pharmaceuticals, Inc., 이하 “이글” 또는 “회사”)(나스닥:EGRX)은 오늘 미국식품의약청(U.S. Food and Drug Administration, 이하 FDA)가 악성고열증(malignant hyperthermia) 치료를 위한 주사용 현탁액(Injectable Suspension)인 라이아노덱스(Ryanodex®, 단트롤렌 나트륨(dantrolene sodium))에 7년 간의 시장독점을 허용했다고 확인했다. 라이...]]></description><pubDate>Tue, 24 Feb 2015 11:55:00 +0900</pubDate></item></channel></rss>